Aeluma, Inc. filings document the reporting record of a Nasdaq-listed emerging growth semiconductor company developing scalable photonic and electronic technologies. Its periodic and current reports cover financial results, quarterly reporting, Regulation FD materials, investor presentations and public-company disclosure controls.
The company’s SEC filings also describe capital-structure activity involving common stock, shelf registration, underwriting agreements and sales-agreement arrangements for registered equity issuance. Governance disclosures include annual meeting voting results, director elections and shareholder approvals, while other current reports address material definitive agreements and Rule 10b5-1 trading-plan disclosures.
Aeluma, Inc. Chief Financial Officer Christopher P. Stewart reported 5,697 shares of common stock delivered or withheld for payment of exercise price or tax liability on September 30, 2026, at a reported price of $12.36 per share. His reported direct post-transaction amount was 67,781 shares, including 41,250 additional shares issuable upon vesting and settlement of existing RSUs previously reported in Table II.
Aeluma, Inc. is soliciting votes at its virtual-only annual meeting on November 19, 2026, for Michael J. Byron’s election to a three-year Class II term and ratification of Rose, Snyder & Jacobs LLP as independent registered public accounting firm for fiscal 2027; the board recommends “FOR” both. Craig H. Ensley is not standing for reelection, and the board has set the number of directorships at four immediately after the meeting, down from the current five. The September 23, 2026 record-date count was 19,314,923 outstanding common shares; 6,438,308 shares constitute a quorum.
The accounting firm’s total fees billed were $167,699 for fiscal 2026, compared with $151,440 for fiscal 2025; the Audit Committee pre-approved all services in both years. Fiscal 2026 total compensation was $690,000 for CEO Jonathan Klamkin, $3,459,904 for CFO Christopher Stewart, and $293,007 for James Seo, Vice President of Finance and former interim CFO. Stewart’s total included $1,145,100 in stock awards and $1,930,940 in option awards.
Aeluma, Inc. (ALMU) approved and adopted amended and restated bylaws on September 29, 2026, reducing the quorum required to hold a stockholder meeting from a majority to one-third (1/3) of the voting power of its issued and outstanding capital stock entitled to vote.
Aeluma, Inc. Chief Financial Officer Stewart Christopher P. reported equity awards on September 21, 2026: 15,886 restricted stock units, 4,042 shares as a stock award in lieu of a cash bonus, and options covering 37,568 shares at a $13.61 exercise price. The RSUs are scheduled to vest and settle 25% on September 30, 2027, then in 12 quarterly increments. The options vest 25% on the first grant anniversary, then in 36 monthly increments. Separately, 1,450 shares were delivered or withheld for payment of exercise price or tax liability.
Aeluma, Inc. CEO and director Jonathan Klamkin reported the sale of 100,000 shares held through a Family Trust on September 21, 2026, at a weighted average $13.3532 per share; the sale was under a Rule 10b5-1 plan adopted May 23, 2026. The trust held 1,226,995 shares after the sale. Klamkin also received 31,771 RSUs, 12,675 shares as a stock award in lieu of a cash bonus, and 75,135 options with a $13.61 exercise price. Separately, 4,547 shares were delivered or withheld for payment of exercise price or tax liability at $13.61 per share.
Aeluma, Inc. director Byron Michael exercised 25,000 fully vested stock options on September 21, 2026, at an exercise price of $5.93 per share, acquiring 25,000 common shares. After the transaction, his reported holdings were 38,343 common shares and 20,833 stock options. No Rule 10b5-1 plan is reported.
Aeluma, Inc. (ALMU) is the issuer of common stock for which the Klamkin Drelle Gelasca Family Trust dated 08/28/2025 has filed a notice to sell shares under Rule 144. The trust plans to sell 100,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.
The planned sale has an aggregate market value of $1,272,500, with 19,265,671 shares of Aeluma common stock stated as outstanding as of the notice, and the securities were originally acquired as Founders Shares on October 27, 2020. In the prior three months, related 10b5-1 sales by Jonathan Klamkin totaled 40,000 shares of common stock.
Aeluma, Inc. (ALMU) reported full-year results for the year ended June 30, 2026, highlighting its transition from primarily R&D activities toward early commercialization of photonic and electronic technologies for AI datacom, mobile, defense, aerospace, and quantum applications. Revenue was $4.46 million, primarily from U.S. government development contracts, and the company remains far from scale production, with commercial orders still small and in qualification.
The net loss widened to $9.16 million as operating expenses more than doubled, driven by higher R&D and general and administrative spending to expand engineering, manufacturing readiness, and go-to-market capabilities. Aeluma strengthened its balance sheet through equity offerings and an at-the-market program, ending the year with $56.01 million in cash and cash equivalents and $60.66 million in total assets, with no debt reported and stockholders’ equity of $56.93 million.
The company describes a capital‑efficient manufacturing model that combines internal epitaxy and prototyping with external foundries such as Tower Semiconductor and Sumitomo Chemical Advanced Technologies. Aeluma also discloses a letter of intent with the U.S. Department of Commerce for potential CHIPS and Science Act funding, which remains subject to definitive agreements, milestones, and possible business restrictions. Management reports a material weakness in internal control over financial reporting related to limited technical accounting resources, and is implementing remediation efforts, including hiring a CFO and engaging a specialist firm.
Aeluma, Inc. (ALMU) reported fourth-quarter and full fiscal year 2026 results for the year ended June 30, 2026. Revenue was $4.46 million, slightly below $4.67 million a year earlier, while the GAAP net loss widened to $9.16 million from $3.02 million, reflecting significantly higher R&D and general and administrative spending.
Adjusted EBITDA declined to -$5.22 million from $0.19 million. Liquidity strengthened, with cash and cash equivalents at $56.01 million, driven mainly by a $43.48 million public offering and warrant exercises, lifting stockholders’ equity to $56.93 million and book value per share to $3.06.
The company highlighted a signed letter of intent with the U.S. Department of Commerce CHIPS R&D Office for up to $30 million in potential funding, an expanded wafer-capacity agreement with Sumitomo Chemical Advanced Technologies, and a strategic shift from early-stage government R&D contracts toward AI datacom commercialization. Aeluma set November 19, 2026 as its next annual stockholder meeting date, with stockholder proposal and nomination notices due by September 26, 2026.